Lesson plan

Fosopamine

Fosopamine ( ; developmental code names SIM-2055, Z-2055; also known as fosfenamine or N-methyldopamine 4-O-phosphate) is a dopamine receptor agonist of the phenethylamine and catecholamine families which was under development for the treatment of hypertension but was never marketed. It is taken orally. Fosopamine is a prodrug of epinine (N-methyldopaine) and is said to be selectively metabolized into epinine in the kidneys. The drug was being developed by AstraZeneca and Zambon Group SpA. It reached phase 2 clinical trials prior to the discontinuation of its development.

Back to article

Article summary

Fosopamine ( ; developmental code names SIM-2055, Z-2055; also known as fosfenamine or N-methyldopamine 4-O-phosphate) is a dopamine receptor agonist of the phenethylamine and catecholamine families which was under development for the treatment of hypertension but was never marketed. It is taken orally. Fosopamine is a prodrug of epinine (N-methyldopaine) and is said to be selectively metabolized into epinine in the kidneys. The drug was being developed by AstraZeneca and Zambon Group SpA. It reached phase 2 clinical trials prior to the discontinuation of its development.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.